Neurol. praxi. 2015;16(4):237-240
Alemtuzumab in multiple sclerosis treatment
- Neurologická klinika 2. LF UK a FN Motol, Praha
Alemtuzumab (Lemtrada®) is a humanized monoclonal antibody indicated for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS).Alemtuzumab causes cytolysis of circulating B and T lymphocytes by binding to their surface marker, CD52. The newly achieved repopulation of lymphocytes subsequently leads to a rebalancing of the immune system. In clinical trials with active comparator (IFN-beta-1a -Rebif 44) demonstrated alemtuzumab superior efficacy when evaluating the annualized relapse rate, progression of disability, the number of new or enlarging lesions on magnetic resonance imaging (MRI) and increasing brain atrophy. Data from clinical trial extensions confirm the long-term effect of alemtuzumab. Its advantage is the low frequency of administration - 5 infusions over 5 days at the start of treatment, and additional 3 infusions per year with the expected efficacy of the treatment scheme for the next 5 years.
Keywords: multiple sclerosis, alemtuzumab, monoclonal antibody, efficacy, safety profile
Published: September 19, 2015 Show citation
References
- Brown JW, Coles AJ. Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis. Drug Des Devel Ther. 2013; 7: 131-138.
Go to original source... 
Go to PubMed... - CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med. 2008; 359(17): 1786-1801.
- Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012; 380(9856): 1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1. PubMed PMID: 23122652. Go to original source... Go to PubMed...
- Haider L. Inflammation, Iron, Energy Failure, and Oxidative Stress in the Pathogenesis of Multiple Sclerosis. Oxid Med Cell Longev. 2015;2015:725370. doi: 10.1155/2015/725370. Epub 2015 May 27. Review. PubMed PMID: 26106458; PubMed Central PMCID: PMC4461760. Go to original source... Go to PubMed...
- Haider L, Fischer MT, Frischer JM, Bauer J, Höftberger R, Botond G, Esterbauer H, Binder CJ, Witztum JL, Lassmann H. Oxidative damage in multiple sclerosis lesions. Brain. 2011 134(Pt 7): 1914-1924. Go to original source... Go to PubMed...
- Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015; 21(1): 22. Go to original source... Go to PubMed...
- Margolin D, Rizzo M, Smith G, Arnold D, Coles A, Hartung H, et al. (2013) Alemtuzumab treatment has no adverse impact on sperm quality, quantity, or motility: A CARE-MS substudy. Presented at 21st World Congress of Neurology, September, Vienna, Austria. Go to original source...
- Havrdová E, Piťha J. Národní sada klinických standardů. 31. Klinický standard pro diagnostiku a léčbu roztroušené sklerózy a neuromyelitis optica. Březen 2012. http://www.czech-neuro.cz/data/q/O/V/0031-rs-odborna.pdf.
- Jones JL, Anderson JM, Phuah CL, et al. Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity. Brain. 2010; 133 Pt 8: 2232-2247. Go to original source...
- Menge T, Stüve O, Kieseier BC, Hartung HP. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 2014; 83(1): 87-97. Go to original source... Go to PubMed...
- Mayer L.,Casady L,Clayton G, et al. Alemtuzumab infusion-associated areactions and mangement in multiple sclerosis. J infus. Nurs 2014; 37: 250-258.